PBAC's latest decision on Lignocaine: Recommended with restriction (2015). Considered for Treatment of post-herpetic neuralgia (PHN), positioning as an alternative to pregabalin and gabapentin in patients with PHN refractory to other drugs.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
—
ICER not stated
Submissions
1
first 2015
Submissions
1
2015 → 2015
Eligible population
Adults with post-herpetic neuralgia (PHN) refractory to treatment with other drugs (Option 1) or unsuitable for or intolerant to pregabalin (Option 2).
Therapy area
Pain
Line of therapy
Later-line
Evidence base
RCT
Primary endpoint
Pain reduction (≥2 points or absolute value ≤4 on NRS-3 scale at Week 4)
Pivotal trial size
311 patients
Key trials
KF10004/03, Binder 2009, Galer 1999, Galer 2002
Comparator
pregabalin
Economic model
CEA
ICER note
ICER value not stated in the public summary document; economic model based on cost-effectiveness comparing treatment algorithms.